4AJ0 Stock Overview Operates as an allergy solutions company in Europe, North America, and internationally. More details
Rewards Risk Analysis No risks detected for 4AJ0 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
ALK-Abelló A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for ALK-Abelló Historical stock prices Current Share Price DKK 20.30 52 Week High DKK 24.56 52 Week Low DKK 13.10 Beta 0.62 1 Month Change -3.33% 3 Month Change -14.99% 1 Year Change 49.37% 3 Year Change -8.10% 5 Year Change 82.72% Change since IPO 386.23%
Recent News & Updates
Alk-Abello A/S Approves in Europe for Treatment of Young Children Dec 13
Third quarter 2024 earnings released: EPS: kr.0.95 (vs kr.0.53 in 3Q 2023) Nov 16
ALK Announces U.S. FDA Approval of New AccuTest Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis Oct 07
Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023) Aug 23
ALK-Abelló A/S Revises Earnings Guidance for the 2024 Aug 23
Now 20% undervalued after recent price drop Aug 09 See more updates
Alk-Abello A/S Approves in Europe for Treatment of Young Children Dec 13
Third quarter 2024 earnings released: EPS: kr.0.95 (vs kr.0.53 in 3Q 2023) Nov 16
ALK Announces U.S. FDA Approval of New AccuTest Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis Oct 07
Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023) Aug 23
ALK-Abelló A/S Revises Earnings Guidance for the 2024 Aug 23
Now 20% undervalued after recent price drop Aug 09
ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy Jun 05
Now 20% undervalued Jun 01
Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review May 31
Now 20% undervalued May 06
Investor sentiment improves as stock rises 22% May 03
First quarter 2024 earnings released May 03 ALK-Abelló A/S Updates Revenue Guidance for the Year 2024
Insider recently sold €1.2m worth of stock Feb 14
Full year 2023 earnings released Feb 08
Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024 Feb 08
Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review Jan 26
ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet Jan 18 ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024
ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024 Nov 17
Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022) Nov 17
Investor sentiment improves as stock rises 18% Nov 15
Alk-Abelló A/S Provides Earnings Guidance for the Year 2023 Nov 15
ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet Oct 12
ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023 Aug 24
Investor sentiment deteriorates as stock falls 17% Jun 22 Alk-Abelló A/S Announces Executive Changes
Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis Jun 09
ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings released May 09
Now 26% undervalued after recent price drop Apr 19 ALK Announces Management Changes
Full year 2022 earnings released Feb 05 ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents Jan 26
ALK-Abelló A/S Announces Executive Changes Dec 22 ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023 ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released Nov 11
ALK-Abelló A/S Provides Earnings Guidance for the Year 2022 Nov 10
Second quarter 2022 earnings released Aug 13
ALK-Abelló A/S Provides Earnings Guidance for the Year 2022 Aug 05
ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy Jun 28
Now 24% undervalued after recent price drop Jun 11
Alk-Abelló A/S Announces Executive Changes May 20
Now 21% undervalued May 14
First quarter 2022 earnings released May 13
ALK-Abelló A/S Provides Earnings Guidance for the Year 2022 May 12
Less than half of directors are independent Apr 27
ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022 Mar 05
Now 20% undervalued after recent price drop Mar 04
Now 20% undervalued after recent price drop Feb 10
Full year 2021 earnings: Revenues in line with analyst expectations Feb 09
ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022 Feb 09
ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022 Feb 08
ALK-Abelló A/S Announces Results from the REACT Study Dec 02
Third quarter 2021 earnings released Nov 12
Second quarter 2021 earnings released Aug 12
ALK-Abelló A/S Revises Earnings Guidance for the Full-Year of 2021 Aug 12
ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC). Jun 05
First quarter 2021 earnings released May 06
ALK Provides Earnings Guidance for the Year 2021 May 05
Revenue misses expectations Feb 12
New 90-day high: €364 Feb 12
Full year 2020 earnings released Feb 12
New 90-day high: €344 Jan 04 ALK-Abelló A/S to Report Q2, 2021 Results on Aug 11, 2021
New 90-day high: €309 Dec 18
Revenue misses expectations Nov 12
New 90-day high: €306 Nov 07
ALK Announces ITULATEK Sublingual Allergy Immunotherapy (Slit)-Tablet Oct 06
ALK-Abelló A/S to Report Q3, 2010 Results on 11/16/2010 Oct 05
Earnings released Aug 12
New 90-day high - €257 Aug 10 Shareholder Returns 4AJ0 DE Pharmaceuticals DE Market 7D -2.9% -2.5% -1.4% 1Y 49.4% -13.7% 8.0%
See full shareholder returns
Return vs Market: 4AJ0 exceeded the German Market which returned 8.1% over the past year.
Price Volatility Is 4AJ0's price volatile compared to industry and market? 4AJ0 volatility 4AJ0 Average Weekly Movement 4.1% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.9% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 4AJ0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4AJ0's weekly volatility (4%) has been stable over the past year.
About the Company Founded Employees CEO Website 1923 2,795 Peter Halling www.alk.net
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
Show more ALK-Abelló A/S Fundamentals Summary How do ALK-Abelló's earnings and revenue compare to its market cap? 4AJ0 fundamental statistics Market cap €4.79b Earnings (TTM ) €105.22m Revenue (TTM ) €721.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4AJ0 income statement (TTM ) Revenue DKK 5.38b Cost of Revenue DKK 1.94b Gross Profit DKK 3.44b Other Expenses DKK 2.66b Earnings DKK 785.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 3.55 Gross Margin 63.96% Net Profit Margin 14.58% Debt/Equity Ratio 3.7%
How did 4AJ0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 01:59 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ALK-Abelló A/S is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Ankersen ABG Sundal Collier Alexandru Cogut Bryan Garnier & Co Jesper Ilsoe Carnegie Investment Bank AB
Show 10 more analysts 
